Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emraclidine - Cerevel Therapeutics

Next Previous
Drug Profile

Emraclidine - Cerevel Therapeutics

Alternative Names: CVL-231; PF-06852231

Latest Information Update: 04 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antidementias; Antipsychotics; Azetidines; Fluorobenzenes; Ketones; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Muscarinic M4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • No development reported Alzheimer's disease

Most Recent Events

  • 21 Aug 2026 Cerevel Therapeutics terminates the phase II EMPOWER-3 trial in Schizophrenia in USA, Bulgaria, Hungary, Peurto Rico, Ukraine due to business reasons, not safety reasons (PO) (NCT05443724) (EudraCT2022-001151-16)
  • 17 Jul 2026 AbbVie completes a phase I pharmacokinetics and relative bioavailability trial (In volunteers) in USA (PO, Tablet) (NCT07587008)
  • 14 May 2026 AbbVie plans a phase I trial in healthy volunteers in May 2026 (PO) (NCT07587008)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top